T988 : PD-L1 IHC, Keytruda for Cervical Cancer W/INTERP.
INFORMATION:
Alternate Name:
PD-L1 Cervical Cancer
Methodology:
Immunohistochemistry
Clinical Utility:
KEYTRUDA® (pembrolizumab) is indicated for the treatment of patients with advanced (recurrent or metastatic) cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS =1) as determined by an FDA approved test. See KEYTRUDA prescribing information for details. Please view full prescribing information at www.fda.gov.
ORDERING:
Test Code:
T988-5
Turnaround Time:
4 DAYS
Preferred Specimen:
Formalin-fixed, Paraffin-embedded Tissue
Collection:
Container | Qty | Temp | Stability |
---|---|---|---|
Formalin-fixed, Paraffin-embedded Tissue | 1 | Room Temp | 999 DAYS |
Collection Instructions:
BLK: This comes in block form from client with surgical number imprint.
Storage Transport Instructions:
Primary Instruction: BLK: This comes in block form from client with surgical number imprint.
Storage/Transport Instruction: Ship with cold pack during warm weather.
Storage/Transport Instruction: Ship with cold pack during warm weather.
Alternative Specimen:
Unstained Slide
Billing:
CPT Codes:
88360 x 1
CPT Code Disclaimer
CPT codes provided are for informational purposes only. Accuracy of CPT presented should be validated prior to consideration for billing.
CPT coding is the sole responsibility of the billing party. Please direct any questions regarding CPT coding to the payer being billed.